DEINOVE overview

CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that on January 23, 2023, the Montpellier Commercial Court rendered a judgment converting the receivership proceedings, initiated on November 7, 2022, into a judicial liquidation proceedings (“ procédure...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, following the Company's request (press release published on October 28, 2022), the Montpellier Commercial Court decided on November 7, 2022 to open receivership proceedings (“ procédure de redressement judiciaire ”) with an observation period (“ période d'observation ”)...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces having filed today a declaration of cessation of payments (" déclaration de cessation des paiements ") and a request for receivership proceedings (“ procédure de redressement judiciaire ”) of the Company with the Montpellier Commercial Court. The employee representative bodies were...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary General Meeting (AGE) held on October 17, 2022 has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favorable to, i.e. 10 out of the 11 resolutions. The shareholders taking part in the vote...

DEINOVE - Adoption of all the ordinary resolutions at the Shareholders’ Meeting of May 30, 2022 The Extraordinary Shareholders’ Meeting will be convened on third notice on July 5, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the General Meeting held on May 30, 2022 on second call has adopted all the...

DEINOVE presents its financial results and the advancement of its programs for 2021 Favorable opinion of the DSMB and continuation of the Phase II of of DNV3837 in the treatment of Clostridioides difficile infection Extension of the trial to 5 new centers in Canada Strengthening of screening and analytical capacities through three complementary calls for projects won by DEINOVE Signature of a new development contract with Royal DSM Group net income 2021 of -€7.0M compared to -€7.3M in 2020,...

Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces today the appointment of Michael MOUREZ, PhD, as Director of Innovation. Michael MOUREZ will oversee the Company's innovation process, developing new growth levers with industrial partners, as well as the methods and...

DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections The DSMB 1 considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The design of the second part of the trial has been modified to integrate the investigators' feedback DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation...